The Inverse OARSI-OMERACT Criteria Is a Valid Indicator of the Clinical Worsening of Knee Osteoarthritis: Data from the Osteoarthritis Initiative

These analyses were financially supported by a public-private partnership comprised 5 contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health (NIH), a branch of the Department of Health and Human Services, and conducted by the Osteoarthritis Initiative (OAI) Study Investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer Inc. Private sector funding for the OAI is managed by the Foundation for the NIH. This manuscript was prepared using an OAI public use dataset and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. The project described was supported by the National Center for Advancing Translational Sciences, NIH, Award Number UL1TR002544. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This work was also supported in part by the Houston Veterans Affairs Health Services Research and Development Center of Excellence (HFP90-020). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. MSH was financially supported by a grant from the NIH (grant no. 5 TL1 TR 1454-3). J.B. Driban, PhD, ATC, CSCS, Associate Professor, T.E. McAlindon, MD, Chief of Rheumatology, Allergy, and Immunology, Division of Rheumatology, Allergy, and Immunology, Tufts Medical Center, Boston; M.S. Harkey, PhD, Postdoctoral Research Fellow, Division of Rheumatology, Allergy, and Immunology, Tufts Medical Center, Boston, and Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester; L.L. Price, MAS, Statistician, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, and Tufts Clinical and Translational Science Institute, Tufts University, Boston, Massachusetts; G.H. Lo, MD, Assistant Professor, Medical Care Line and Research Care Line, Houston Health Services Research and Development (HSR&D) Center of Excellence Michael E. DeBakey VAMC, and Section of Immunology, Allergy, and Rheumatology Baylor College of Medicine, Houston, Texas, USA. The authors have no other conflicts of interest with regard to this work. Address correspondence to Dr. J.B. Driban, Division of Rheumatology, Tufts Medical Center, 800 Washington Street, Box 406, Boston, MA 02111, USA. Email: jeffrey.driban@tufts.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 26, 2020.

These analyses were financially supported by a public-private partnership comprised 5 contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health (NIH), a branch of the Department of Health and Human Services, and conducted by the Osteoarthritis Initiative (OAI) Study Investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer Inc. Private sector funding for the OAI is managed by the Foundation for the NIH. This manuscript was prepared using an OAI public use dataset and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. The project described was supported by the National Center for Advancing Translational Sciences, NIH, Award Number UL1TR002544. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This work was also supported in part by the Houston Veterans Affairs Health Services Research and Development Center of Excellence (HFP90-020). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. MSH was financially supported by a grant from the NIH (grant no. 5 TL1 TR 1454-3). J.B. Driban, PhD, ATC, CSCS, Associate Professor, T.E. McAlindon, MD, Chief of Rheumatology, Allergy, and Immunology, Division of Rheumatology, Allergy, and Immunology, Tufts Medical Center, Boston; M.S. Harkey, PhD, Postdoctoral Research Fellow, Division of Rheumatology, Allergy, and Immunology, Tufts Medical Center, Boston, and Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester; L.L. Price, MAS, Statistician, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, and Tufts Clinical and Translational Science Institute, Tufts University, Boston, Massachusetts; G.H. Lo, MD, Assistant Professor, Medical Care Line and Research Care Line, Houston Health Services Research and Development (HSR&D) Center of Excellence Michael E. DeBakey VAMC, and Section of Immunology, Allergy, and Rheumatology Baylor College of Medicine, Houston, Texas, USA. The authors have no other conflicts of interest with regard to this work. Address correspondence to Dr. J.B. Driban, Division of Rheumatology, Tufts Medical Center, 800 Washington Street, Box 406, Boston, MA 02111, USA. Email: jeffrey.driban@tufts.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 26, 2020.

These analyses were financially supported by a public-private partnership comprised 5 contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health (NIH), a branch of the Department of Health and Human Services, and conducted by the Osteoarthritis Initiative (OAI) Study Investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer Inc. Private sector funding for the OAI is managed by the Foundation for the NIH. This manuscript was prepared using an OAI public use dataset and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. The project described was supported by the National Center for Advancing Translational Sciences, NIH, Award Number UL1TR002544. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This work was also supported in part by the Houston Veterans Affairs Health Services Research and Development Center of Excellence (HFP90-020). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. MSH was financially supported by a grant from the NIH (grant no. 5 TL1 TR 1454-3). J.B. Driban, PhD, ATC, CSCS, Associate Professor, T.E. McAlindon, MD, Chief of Rheumatology, Allergy, and Immunology, Division of Rheumatology, Allergy, and Immunology, Tufts Medical Center, Boston; M.S. Harkey, PhD, Postdoctoral Research Fellow, Division of Rheumatology, Allergy, and Immunology, Tufts Medical Center, Boston, and Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester; L.L. Price, MAS, Statistician, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, and Tufts Clinical and Translational Science Institute, Tufts University, Boston, Massachusetts; G.H. Lo, MD, Assistant Professor, Medical Care Line and Research Care Line, Houston Health Services Research and Development (HSR&D) Center of Excellence Michael E. DeBakey VAMC, and Section of Immunology, Allergy, and Rheumatology Baylor College of Medicine, Houston, Texas, USA. The authors have no other conflicts of interest with regard to this work. Address correspondence to Dr. J.B. Driban, Division of Rheumatology, Tufts Medical Center, 800 Washington Street, Box 406, Boston, MA 02111, USA. Email: jeffrey.driban@tufts.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 26, 2020.

These analyses were financially supported by a public-private partnership comprised 5 contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health (NIH), a branch of the Department of Health and Human Services, and conducted by the Osteoarthritis Initiative (OAI) Study Investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer Inc. Private sector funding for the OAI is managed by the Foundation for the NIH. This manuscript was prepared using an OAI public use dataset and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. The project described was supported by the National Center for Advancing Translational Sciences, NIH, Award Number UL1TR002544. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This work was also supported in part by the Houston Veterans Affairs Health Services Research and Development Center of Excellence (HFP90-020). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. MSH was financially supported by a grant from the NIH (grant no. 5 TL1 TR 1454-3). J.B. Driban, PhD, ATC, CSCS, Associate Professor, T.E. McAlindon, MD, Chief of Rheumatology, Allergy, and Immunology, Division of Rheumatology, Allergy, and Immunology, Tufts Medical Center, Boston; M.S. Harkey, PhD, Postdoctoral Research Fellow, Division of Rheumatology, Allergy, and Immunology, Tufts Medical Center, Boston, and Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester; L.L. Price, MAS, Statistician, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, and Tufts Clinical and Translational Science Institute, Tufts University, Boston, Massachusetts; G.H. Lo, MD, Assistant Professor, Medical Care Line and Research Care Line, Houston Health Services Research and Development (HSR&D) Center of Excellence Michael E. DeBakey VAMC, and Section of Immunology, Allergy, and Rheumatology Baylor College of Medicine, Houston, Texas, USA. The authors have no other conflicts of interest with regard to this work. Address correspondence to Dr. J.B. Driban, Division of Rheumatology, Tufts Medical Center, 800 Washington Street, Box 406, Boston, MA 02111, USA. Email: jeffrey.driban@tufts.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 26, 2020.

These analyses were financially supported by a public-private partnership comprised 5 contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health (NIH), a branch of the Department of Health and Human Services, and conducted by the Osteoarthritis Initiative (OAI) Study Investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer Inc. Private sector funding for the OAI is managed by the Foundation for the NIH. This manuscript was prepared using an OAI public use dataset and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. The project described was supported by the National Center for Advancing Translational Sciences, NIH, Award Number UL1TR002544. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This work was also supported in part by the Houston Veterans Affairs Health Services Research and Development Center of Excellence (HFP90-020). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. MSH was financially supported by a grant from the NIH (grant no. 5 TL1 TR 1454-3). J.B. Driban, PhD, ATC, CSCS, Associate Professor, T.E. McAlindon, MD, Chief of Rheumatology, Allergy, and Immunology, Division of Rheumatology, Allergy, and Immunology, Tufts Medical Center, Boston; M.S. Harkey, PhD, Postdoctoral Research Fellow, Division of Rheumatology, Allergy, and Immunology, Tufts Medical Center, Boston, and Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester; L.L. Price, MAS, Statistician, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, and Tufts Clinical and Translational Science Institute, Tufts University, Boston, Massachusetts; G.H. Lo, MD, Assistant Professor, Medical Care Line and Research Care Line, Houston Health Services Research and Development (HSR&D) Center of Excellence Michael E. DeBakey VAMC, and Section of Immunology, Allergy, and Rheumatology Baylor College of Medicine, Houston, Texas, USA. The authors have no other conflicts of interest with regard to this work. Address correspondence to Dr. J.B. Driban, Division of Rheumatology, Tufts Medical Center, 800 Washington Street, Box 406, Boston, MA 02111, USA. Email: jeffrey.driban@tufts.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication May 26, 2020.